在患有状细胞贫血的儿童中进行初级和二级中风预防:元分析
Hemalatha G Rangarajan1, Jose A Mejias2, Alison Paige Gehred3
1Nationwide Childrens Hosptial, Columbus, Ohio, United States.
Blood advances
|October 10, 2025
概括
水氧尿素 (HU) 和慢性输血 (CBT) 显著降低了患有状细胞贫血 (SCA) 的儿童中风风险. HU是低资源环境中预防中风的具有成本效益的选择.
科学领域:
- 血液学 血液学 血液学
- 儿科神经学 儿科神经学
- 公共卫生 公共卫生
背景情况:
- 状细胞贫血 (SCA) 对儿童造成中风的风险很高.
- 有效的初级和二级中风预防策略对于管理SCA至关重要.
研究的目的:
- 评估氧尿素 (HU),慢性输血 (CBT),造血干细胞移植 (HCT) 和重血管化手术 (RVS) 在SCA儿童中风预防方面的比较有效性.
- 将这些干预措施与没有治疗进行比较.
主要方法:
- 来自Medline和EMBASE数据库的综合分析 (至少六名患者,2025年1月之前).
- 四名审查员评估了研究的共识.
- 对初级和二级预防的中风率进行了分析.
主要成果:
- 初级中风预防 (横多普勒>200厘米/秒):没有治疗 (10.7/100人/年),HU (1.0/100人/年),CBT (1.0/100人/年).
- 二次中风预防:没有治疗 (19.6/100人/年),HU (3.5/100人/年),CBT (2.7/100人/年),HCT (1.0/100人/年),RVS (3.3/100人/年).
- 由于缺乏依赖时间的调整,HCT和RVS可能会高估收益.
结论:
- HU和CBT有效降低SCA儿童中风风险.
- 在低中等收入国家 (LMICs),HU是预防中风的可访问和负担得起的选择,未接受治疗的儿童中,中风复发率为36.4-51.4/100人年.
- HU的低成本 (<0.20美元/天) 使其成为在资源有限的环境中用于SCA中风预防的实用选择.
更多相关视频
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
20.3K
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
10.3K
相关概念视频
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
192
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
192
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
252
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
252
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
242
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
242
01:29Drug Dosing: Infants and Children
253
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
253
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212